title: Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
abstract: We analyzed the differential gene expression between variants of MDA-MB-435 human breast cancer cell line that share an identical genetic background but have different metastatic ability. The major histocompatibility complex class II was found down-regulated in highly metastatic cells and correlated with MHC transactivator (CIITA) expression. Constitutive CIITA expression observed in poorly metastatic is driven by promoters III and IV of CIITA gene. Conversely, both promoters were ineffective in highly metastatic cells. The MHC class II and CIITA expression was restored in these cells upon stimulation with IFNgamma or by the treatment with a hypomethylating agent. Both treatments induced USF-1 and IRF binding complexes to promoter IV but only IFNgamma induced the binding of 435-Lung2 nuclear proteins to an ARE-1 site at the promoter III. Neither Southern blot nor bisulfite sequencing of promoter IV demonstrated strong hypermethylation of this promoter at the IFNgamma-responsive elements such as GAS, E-box or IRF-1. We suggest that partial or hemimethylation of promoter IV is sufficient to silence the CIITA expression in highly metastatic cells and that this epigenetic mechanism is responsible for the lack of MHC-II expression. Forced CIITA expression restored the MHC-II antigen expression in 435-Lung2 cells and abrogates spontaneous lung metastasis in both SCID and nude mice but also affected the tumorigenicity in nude mice. The increase in NK cell infiltration in nude mice bearing CIITA-tumors correlated with sign of tumor cell apoptosis and the increase in the number of NK cells in the spleens, suggesting that NK cells might be responsible for the observed antitumor activity.
authors.affiliation: Institut de Recerca Oncologica, Hospital Duran i Reynals, Autovia de Castelldefels Km 2,7, Hospitalet de Llobregat, Barcelona 08907, Spain.
authors.forename: Bo
authors.initials: B
authors.lastname: Shi
authors.forename: Antònia
authors.initials: A
authors.lastname: Vinyals
authors.forename: Pedro
authors.initials: P
authors.lastname: Alia
authors.forename: Cristina
authors.initials: C
authors.lastname: Broceño
authors.forename: Feisong
authors.initials: F
authors.lastname: Chen
authors.forename: Marc
authors.initials: M
authors.lastname: Adrover
authors.forename: Carme
authors.initials: C
authors.lastname: Gelpi
authors.forename: Janet E
authors.initials: JE
authors.lastname: Price
authors.forename: Angels
authors.initials: A
authors.lastname: Fabra
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D019175:DNA Methylation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis* / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000235:genetics / Q000276:immunology / Q000473:pathology; D009363:Neoplasm Proteins / Q000276:immunology / Q000378:metabolism*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009687:Nuclear Proteins / Q000276:immunology / Q000378:metabolism*; D020218:Response Elements / Q000276:immunology; D015534:Trans-Activators / Q000276:immunology / Q000378:metabolism*
chemical_list: D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015534:Trans-Activators